Search by Drug Name or NDC
NDC 00006-5368-03 STEGLUJAN 15; 100 mg/1; mg/1 Details
STEGLUJAN 15; 100 mg/1; mg/1
STEGLUJAN is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is ERTUGLIFLOZIN PIDOLATE; SITAGLIPTIN PHOSPHATE.
MedlinePlus Drug Summary
Ertugliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Ertugliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Ertugliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 00006-5368-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ertugliflozin
Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high. Sitagliptin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 00006-5368-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Sitagliptin
Product Information
| NDC | 00006-5368 |
|---|---|
| Product ID | 0006-5368_21cf231e-a04e-4f5b-82ab-b872482550f9 |
| Associated GPIs | 27996502350330 |
| GCN Sequence Number | 078037 |
| GCN Sequence Number Description | ertugliflozin/sitagliptin phos TABLET 15MG-100MG ORAL |
| HIC3 | C4W |
| HIC3 Description | ANTIHYPERGLYCEMIC, SGLT-2 AND DPP-4 INHIBITOR COMB |
| GCN | 44238 |
| HICL Sequence Number | 044706 |
| HICL Sequence Number Description | ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE |
| Brand/Generic | Brand |
| Proprietary Name | STEGLUJAN |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ertugliflozin and sitagliptin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 15; 100 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | ERTUGLIFLOZIN PIDOLATE; SITAGLIPTIN PHOSPHATE |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA209805 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00006-5368-03 (00006536803)
| NDC Package Code | 0006-5368-03 |
|---|---|
| Billing NDC | 00006536803 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (0006-5368-03) |
| Marketing Start Date | 2017-12-19 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 17.6655 |
| Pricing Unit | EA |
| Effective Date | 2023-07-19 |
| NDC Description | STEGLUJAN 15-100 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |